Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer?
Corcoran
N M
NM
Department of Urology, Royal Melbourne Hospital, Parkville, Victoria, Australia. Niall.Corcoran@mh.org.au
Costello
A J
AJ
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D015850:Interleukin-6 / Q000502:physiology*; D008297:Male; D020929:Mitogen-Activated Protein Kinase Kinases / Q000502:physiology; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011944:Receptors, Androgen / Q000502:physiology; D019947:Receptors, Interleukin-6 / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology
D018931:Antineoplastic Agents, Hormonal; D015850:Interleukin-6; D011944:Receptors, Androgen; D019947:Receptors, Interleukin-6; D020929:Mitogen-Activated Protein Kinase Kinases